Cat. No.: HY-15260

XL413

Name: XL413
Brand: MedChemExpress
SKU: HY-15260
Price: 144.00 USD
Availability: InStock
Rating: 5 (8 reviews)

(Synonyms: BMS-863233)

8 Cited Publications

Customer Review

Based on 8 publication(s) in Google Scholar

XL413 (BMS-863233) is an orally active, ATP-competitive, selective CDC7 kinase inhibitor. XL413 reduces MCM2 phosphorylation levels, decreases DNA replication origin activation, and inhibits CD69 upregulation in stimulated lymphocytes. XL-413 possesses cell-dependent antiproliferative and pro-apoptotic activities. XL413 attenuates ATR inhibitor-induced excessive origin activation, altered replication fork speed, and antiproliferative effects in sensitive cancer cells. XL413 inhibits SARS-CoV-2 infection. XL413 can be used for research related to cancer and SARS-CoV-2 infection.

For research use only. We do not sell to patients.

Purity : 99.02%
CAS No.: 1169558-38-6
Formula: C₁₄H₁₂ClN₃O₂
Molecular Weight:289.72

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

XL413 Chemical Structure

CAS No.: 1169558-38-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[3]^[4]

Cdc7

3.4 nM (IC₅₀)

Caspase 3

Caspase-7

All CDK Isoforms :

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	EC₅₀	2288 nM Compound: 14, XL413	Induction of apoptosis in human Caco2 cells assessed as increase in caspase 3/7 activity Induction of apoptosis in human Caco2 cells assessed as increase in caspase 3/7 activity	[PMID: 22560567]
Caco-2	ED₅₀	<3 mg/kg Compound: 14, XL413	Inhibition of CDC7-mediated MCM2 phosphorylation at Ser40/41 in human Caco2 cells xenografted in po dosed athymic nude mouse by after 4 hrs Western blot analysis Inhibition of CDC7-mediated MCM2 phosphorylation at Ser40/41 in human Caco2 cells xenografted in po dosed athymic nude mouse by after 4 hrs Western blot analysis	[PMID: 22560567]
Caco-2	IC₅₀	140 nM Compound: 14, XL413	Inhibition of CDC7 in human Caco2 cells assessed as inhibition of MCM2 phosphorylation at Ser53 after 4 hrs Inhibition of CDC7 in human Caco2 cells assessed as inhibition of MCM2 phosphorylation at Ser53 after 4 hrs	[PMID: 22560567]
Caco-2	IC₅₀	2142 nM Compound: 14, XL413	Antiproliferative activity against human Caco2 cells assessed as decrease in cell viability after 3 days by Cell Titer-Glo assay Antiproliferative activity against human Caco2 cells assessed as decrease in cell viability after 3 days by Cell Titer-Glo assay	[PMID: 22560567]
Caco-2	IC₅₀	2685 nM Compound: 14, XL413	Antiproliferative activity against human Caco2 cells after 3 days by BrdU incorporation assay Antiproliferative activity against human Caco2 cells after 3 days by BrdU incorporation assay	[PMID: 22560567]
Caco-2	IC₅₀	715 nM Compound: 14, XL413	Antiproliferative activity against human Caco2 cells assessed as inhibition of anchorage-independent growth in soft agar Antiproliferative activity against human Caco2 cells assessed as inhibition of anchorage-independent growth in soft agar	[PMID: 22560567]

In Vitro

XL-413 (1 µM; 1 h) reduces baseline origin activation levels and reverses ATRi-induced alterations in origin density and replication fork speed in HCC1806 breast cancer cells; it decreases EdU incorporation and inhibits ATRi-induced replication origin hyperactivation in HCC1806 breast cancer cells^[1].
XL-413 (0.25 µM; 72 h) partially rescues ATRi-mediated antiproliferative effects in the sensitive breast cancer cell lines HCC1806 and HCC1569^[1].
XL-413 (BMS-863233) exhibits antiviral activity against infectious SARS-CoV-2 in Calu-1 cells and produces cytotoxic effects at higher concentrations^[2].
XL-413 shows no detectable modulation of DDX39B-related protein-protein interactions at concentrations of 5 μM and 50 μM in HEK293 cells^[2].
XL-413 exhibits potent inhibitory activity against purified recombinant DDK (Cdc7-Dbf4) kinase, with IC₅₀ = 22.7 nM^[4].
XL-413 (5 μM; 24-72 h) abolishes DDK-dependent MCM2 phosphorylation in Colo-205 cells, whereas only a slight decrease in MCM2 phosphorylation is observed at 72 h in HCC1954 cells^[4].
XL-413 potently and selectively inhibits CDC7 kinase activity in Jurkat cells and OT-I CTLs; it inhibits CDC7 with an IC₅₀ of 3.4 nM in biochemical assays^[3].
XL-413 inhibits the expression of the early T cell activation marker CD69 in anti-CD3-stimulated mouse lymphocytes^[3].
XL-413 (5 μM; 72 h) exhibits potent antiproliferative and pro-apoptotic activity against Colo-205 colorectal cancer cells (IC₅₀ = 1.1 μM), but shows weak antiproliferative effects on HCC1954 breast cancer cells (IC₅₀ = 22.9 μM)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

HCC1806 and HCC1569 breast cancer cells
Concentration:

0.25 µM (co-administered with ATRi)
Incubation Time:

72 h
Result:

Reduced the anti-proliferative effect of ATRi in both HCC1806 and HCC1569 ATRi-sensitive breast cancer cell lines, indicating partial rescue of ATRi sensitivity when origin firing capacity is lowered via CDC7 inhibition.

Cell Viability Assay^[4]

Cell Line:

HCC1954, HeLa, MDA‑MB‑231, HCC1187, BT‑549, MDA‑MB‑453 and MCF‑7 tumor cell lines
Concentration:

5 μM
Incubation Time:

72 h
Result:

Displayed weak antiproliferative activity against HCC1954, HeLa, MDA‑MB‑231, HCC1187, BT‑549, MDA‑MB‑453 and MCF‑7 tumor cell lines, while it shows strong antiproliferative activity against Colo‑205 tumor cells.

Western Blot Analysis^[4]

Cell Line:

Colo-205 cells
Concentration:

5 μM
Incubation Time:

0, 24, 48, 72 h
Result:

Abolished DDK-dependent MCM2 phosphorylation in Colo-205 cells, whereas only a slight decrease in MCM2 phosphorylation is observed at 72 h in HCC1954 cells.

In Vivo

XL-413 (p.o.) exhibits potent anticancer activity against Colo-205 xenograft tumors in mice, and shows good drug tolerability at oral doses up to 100 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1169558-38-6
Appearance Solid
Molecular Weight 289.72
Formula C₁₄H₁₂ClN₃O₂
Color Off-white to light yellow
SMILES

ClC1=CC=C2C(C(N=C([C@@H]3CCCN3)NC4=O)=C4O2)=C1
Synonyms

BMS-863233
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (8)

All WB

Sort by:

Journal Impact Factor

Science

The target landscape of clinical kinase drugs. [Abstract]

2017 Dec 1;358(6367):eaan4368. PMID: 29191878
MedComm (2020)

PRMT5 Promotes Pancreatic Cancer Tumorigenesis via Positive PRMT5/C-Myc Feedback Loop. [Abstract]

2025 May 15;6(6):e70150. PMID: 40384988
J Transl Med

2026 Jul 11. PMID: 42436511
Sens Actuators B Chem

15 May 2022, 131618.
Oncogenesis

Cyclin E modulates vulnerability to CDC7 kinase inhibition. [Abstract]

2026 Apr 24;15(1):27. PMID: 42031714
Am J Physiol Lung Cell Mol Physiol

Cell division cycle 7 kinase is a negative regulator of cell-mediated collagen degradation. [Abstract]

2018 Sep 1;315(3):L360-L370. PMID: 29792348

XL413 purchased from MedChemExpress. Usage Cited in: Am J Physiol Lung Cell Mol Physiol. 2018 Sep 1;315(3):L360-L370. [Abstract]

Representative Western blot for Endo180 expression in U937 cells treated overnight with XL413.
bioRxiv

2025 Dec 9.
University of Washington

2025.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lumeau A, et al. High levels of DNA replication initiation factors indicate ATRi sensitivity via excessive origin firing[EB/OL]. bioRxiv, 2025.

[2]. Liu X, et al. SARS-CoV-2-host proteome interactions for antiviral drug discovery. Molecular systems biology. 2021 Nov;17(11):e10396. [Content Brief]

[3]. Chen EW, et al. A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation. Frontiers in immunology. 2019;10:1718. [Content Brief]

[4]. Sasi NK, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014 Nov 20;9(11):e113300. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

XL413

Publications Citing Use of MedChemExpress (MCE) XL413

All CDK Isoforms

All Caspase Isoforms